---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-092272"
form_type: "8-K"
ticker: "KYMR"
cik: "0001815442"
company_name: "Kymera Therapeutics, Inc."
filed_at: "2024-08-07T23:59:59+00:00"
generated_at: "2026-05-31T11:51:44.090876+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Kymera Q2 net loss $42.1M, cash $702M; Sanofi expands KT-474 Phase 2

## Summary
- Net loss $42.1M in Q2 2024 vs $38.8M in Q2 2023; revenue from Sanofi collaboration $25.7M.
- Cash & equivalents $702M as of June 30, 2024; projected runway into first half 2027.
- Sanofi plans to expand KT-474 (IRAK4) Phase 2 trials in HS and AD after interim safety/efficacy review.
- STAT6 degrader KT-621 Phase 1 on track for H2 2024; TYK2 degrader KT-294 Phase 1 in H1 2025.
- KT-253 (MDM2) and KT-333 (STAT3) Phase 1a enrollment completion expected H2 2024 with data presentations.

## SEC filing metadata
- accession: 0000950170-24-092272
- form_type: 8-K
- ticker: KYMR
- cik: 0001815442
- company_name: Kymera Therapeutics, Inc.
- filed_at: 2024-08-07T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1815442/000095017024092272/0000950170-24-092272-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1815442/000095017024092272/kymr-20240807.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-092272
- JSON: https://secwatch.observer/filing/0000950170-24-092272.json
- Plain text: https://secwatch.observer/filing/0000950170-24-092272.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.